AlloVir (NASDAQ:ALVR) reported quarterly losses of $(0.72) per share. This is a 24.14 percent decrease over losses of $(0.58) per share from the same period last year.
RBC Capital Maintains Outperform on Pacira BioSciences, Lowers Price Target to $76
RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:PCRX) with a Outperform and lowers the price target from $80 to $76.